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Effect of azithromycin on primary
bronchial epithelial cells derived
from stable lung allografts
Obliterative bronchiolitis (OB), the main cause
of lung allograft failure, is characterised by
airway inflammation, neutrophilia, remodel-
ling and fibrosis. Recent studies of the macro-
lide antibiotic azithromycin in OB, including
one from our centre, have reported improved
lung function with rescue therapy.1 The
mechanism for this improvement remains
unclear, but a recent study suggests that
neutrophilic inflammation may be an impor-
tant predictor of clinical response.2
Macrolides have anti-inflammatory proper-
ties in several pulmonary conditions. We
hypothesised that the clinical benefit observed
with azithromycin in patients undergoing lung
transplantation may be related to the inhibi-
tion of factors key to airway neutrophilic
inflammation, remodelling and fibrosis. The
bronchial epithelium is in a pivotal position as
a target and orchestrator of airway inflamma-
tion and remodelling. We tested our hypothesis
using a unique primary bronchial epithelial cell
(PBEC) model.3 The local research ethics
committee approved the study.
Following pre-bronchoscopic assessment, sur-
veillance bronchoscopy and bronchoalveolar
lavage microbiology were performed to rule out
infection. Bronchial brushings were obtained
from subsegmental bronchi for PBEC cultures.
Transbronchial specimens were examined to
exclude acute vascular rejection. PBECs were
established using endobronchial brushings from
10 clinically stable transplant recipients.
Azithromycin (Pfizer Ltd, Sandwich, UK) 20,
10 and 5 ng/ml was added to PBECs for 48 h
before removal of cell supernatant and protein
analysis with multiplex kits (R&D Systems
Europe Ltd, Abingdon, UK) and a Luminex
analyser. A methylene blue assay was used to
correct data for PBEC cell number and the data
were analysed using the Wilcoxon signed rank
test.
Azithromycin caused a significant decrease
in matrix metalloproteinase (MMP)-2, inter-
leukin (IL)-8, granulocyte-macrophage colony
stimulating factor (GM-CSF) and MMP-9
levels, with a trend towards decreased IL-6
production (table 1). Basal MMP-9 (2/10) and
MMP-2 and GM-CSF levels (3/10) were below
detection limits in some PBEC cultures. These
factors are critical in orchestrating neutrophil
influx, influencing antigen presenting cells and
potentiating airway remodelling, which are
relevant to the pathophysiology of OB. IL-8 is
a neutrophil chemoattractant with additional
roles in angiogenesis and remodelling, while
IL-6 plays a part in B cell differentiation,
monocyte proliferation, neutrophil recruit-
ment, activation and degranulation, which
may have pathophysiological roles in OB.
GM-CSF regulates accumulation and activity
of neutrophils and is increased in lung disease
characterised by neutrophilic infiltration and
in the post-transplant airway.4 It is also
associated with an increased number and
activity of antigen presenting cells, including
activated dendritic cells.
It is assumed that fibroblasts are responsible
for the production of scar collagen in chronic
transplant rejection. We have shown potential
for injured airway epithelial cells from allo-
grafts to become fibroblasts through epithelial
mesenchymal transition (EMT) and have
demonstrated a key role for MMPs in facilitat-
ing this phenotypic change.5 The ability of
azithromycin to modulate the epithelial release
of these factors is therefore consistent with a
potential to influence alloimmunity, neutro-
philic inflammation, EMT, remodelling and
fibrosis. We therefore suggest that this may
underlie the clinical benefit of azithromycin
seen in certain patients, but further animal
model and in vivo studies including random-
ised trials are required.
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Critical care as part of respiratory
training in the UK
Experience in critical care medicine is manda-
tory for all respiratory trainees in the UK with a
need for 60 days (3 months) minimum place-
ment in an intensive care unit (ICU). The
Respiratory Critical Care Group of the British
Thoracic Society1 recently reported a survey in
which there was widespread agreement with
this requirement, although it was inadequately
provided by a number of programmes. In
addition, a proportion of trainees indicated
the intention to subspecialise in intensive care
medicine and were concerned that their ICU
experience was diluted by having responsibil-
ities such as acute general medical takes during
their attachment. We recently carried out an
email survey of anaesthetic and respiratory
trainees and directors of intensive care which
provides additional useful information.
The majority of ICUs in the UK operate an
admission policy that depends on making
initial contact with the duty anaesthetic
registrar. One aspect of our survey concerned
the interaction between the referring physician
and the critical care ‘‘gate keeping’’ specialist.
Although it might be optimal to involve the
appropriate medical, emergency or surgical con-
sultant directly in making a referral to the critical
care consultant, it is often specialist registrars
who refer patients, especially out of hours.
Our survey investigated whether the speci-
alty of the referring specialist registrar affected
the outcome. A total of 108 doctors (97
specialist registrars and 9 ICU lead consul-
tants) from South Thames, West Midlands and
Oxford regions were surveyed in 2006. Of the
respiratory specialist registrars, 27% indicated
they ‘‘commonly’’ or ‘‘always’’ had difficulty
gaining admission for medical patients. No
anaesthetic trainee reported difficulty ‘‘com-
monly’’ or ‘‘always’’ while 47% reported that
Table 1 Effect of azithromycin at concentrations of 5, 10 and 20 ng/ml on IL-8,
GM-CSF, IL-6, MMP-2 and MMP-9 levels
Azithromycin
concentration
(ng/ml)
IL-8 ng/106
cells (n = 10)
GM-CSF
ng/106 cells
(n = 7)
MMP-9
ng/106 cells
(n = 8)
MMP-2
ng/106 cells
(n = 7)
IL-6
pg/106 cells
(n = 3)
0 4.4 (0.6–13.0) 1.1 (0.1–5.5) 34.2 (5.5–65.6) 2.2 (0.4–8.7) 54.6 (36.4–
238.0)
5 3.4 (0.5–14.5) 0.6 (0.1–4.3) 20.4 (3.9–66.4)* 1.0 (0.4–4.1) 37.0 (24.7–91.6)
10 2.2 (0.4–16.9) 0.4 (0.1–3.3) 20.5 (3.6–93.9) 1.2 (0.4–6.9)* 39.3 (36.8–71.0)
20 1.8 (0.2–7.3)** 0.5 (0.1–2.9)* 14.6 (1.4–35.1)** 0.6 (0.4–5.0)* 35.0 (21.6–46.4)
IL, interleukin; GM-CSF, granulocyte-macrophage colony stimulating factor; MMP, matrix metalloproteinase.
Data shown are median (range) values.
Experiments were analysed for n = 10 for IL-8, n = 8 for MMP-9, and n = 7 for both MMP-2 and GM-CSF. Where azithromycin
decreased analyte levels below the assay detection limit, a value halfway between the lowest level of the detection range and
zero was assigned. The Wilcoxon signed rank test was used to test for statistical significance with a two-sided p value ,0.05
deemed significant. *p,0.05; **p,0.01. IL-6 data (n = 3) were not statistically analysed.
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